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ABSTRACT
The efficacy of oral amphotericin B (ApB) was studied 
in 125 cases of refractory atopic dermatitis (AD). 
Indications for ApB therapy were positive CAP-RAST 
(Pharmacia & Upjohn Co. Ltd)-class to Candida 
albicans and several food allergens and a high intake 
of sweets or alcoholic beverages together with 
recalcitrant symptoms of AD, such as facial erythema 
and eruptions refractory to topical steroids. Good or 
excellent results were obtained in 56.8% of 125 cases. 
Assessment of improvement in the 125 subjects was 
statistically compared with that in 55 controls who 
were not treated with ApB. There were no significant 
differences in the background between the two study 
groups. Cases treated with oral ApB showed 
significantly greater improvement (P<0.01) than did 
the controls, who were not treated with ApB, over 3 
and 6 month periods. Treatment with ApB helped 
patients to discontinue or to reduce the frequency of 
topical steroid use or to change from high-dose 
steroids to lower-dose steroids. Treatment of patients 
with oral ApB resulted in improvements in laboratory 
data, including CAP PAST to C. albicans and several 
food allergens. Good results were associated with 
restricting the intake of food allergens. A poor
response was recognized in patients with a 
significantly high titer of CAP-PAST levels to 
Dermatophagoides farinae. Controlling environmental 
allergens and limiting exposure to food allergens was 
necessary to achieve success with ApB treatment.
Key words: amphotericin B, antifungal therapy, atopic 
dermatitis, Candida albicans, food allergy.
INTRODUCTION
The pathogenesis of atopic dermatitis (AD) has not yet 
been clarified and is supposed to be multifactorial. In 
treating AD, the majority of practitioners have found that 
AD is controlled by avoiding allergens and irritants, 
taking care of dry skin, eating a balanced diet and 
managing stress, together with application of topical 
medication and systemic anti-allergic drugs. However, 
management of AD refractory to conventional therapy 
remains controversial. Efficacy of antifungal therapy1-4 
has been reported for recalcitrant AD. It is well known that 
Candida species are normal commensals of humans and 
one of the most common causes of internal infection.5 
Concerning Candida sensitization and skin disease, in 
some cases of unccaria,6 Candida albicans has been 
reported to be a pathogenic factor. A principle in treating 
allergic diseases resulting from fungi is the avoidance of 
fungi as allergens. Candida spp. live in our environment 
but are mainly found internally, especially in the digestive 
tract, as one of the microflora.5 Therefore, to avoid 
Candida as an allergen, administration of an anti-
Candida drug is advisable. Matsuda et al.1 suggested 
that colonization of Candida in the digestive tract and
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sensitization to Candida may be involved in aggravation 
or persistence of recalcitrant AD and they reported the 
efficacy of oral nystatin (Ny), an anti-Candida drug. Suga 
et al.7 also reported the efficacy of anti-Candida drugs on 
refractory symptoms of AD and emphasized that 
combining a restricted diet for food allergy with 
antifungal therapy affects the efficacy of the drugs. 
However, there has not yet been a control study 
performed to assess the efficacy of anti-Candida drugs. 
Nystatin and ApB are polyene antifungal drugs, 
damaging the cell membrane of fungal cells, and their 
absorption through the gastrointestinal tract is highly 
limited.8 Amphotericin B has a better minimal inhibitory 
concentration than Ny.8 The present study assessed the
efficacy of anti-Candida therapy using oral ApB in 
tr ating patients who failed to respond to conventional 
therapy and statistically compared improvement in these 
patients with that in controls who did not receive ApB 
therapy.
METHODS
Subjects and their background characteristics
The present investigation was performed between June 
1992 and September 1995. The subjects of the study 
were 125 outpatients (61 males and 64 females) with AD 
in the outpatient clinic of the Dermatological Department
Table 1. Clinical and laboratory data of patients receiving oral ApB (group I) and those not receiving oral ApB (group II)
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of Yokohama City University Urafune Hospital, 
Yokohama Children's Allergy Center and an affiliated 
clinic. In these subjects diagnosis of AD was compatible 
with the definition and diagnostic criteria for AD given by 
the Japanese dermatological association.9 Clinical and 
laboratory characteristics of the patients are given in 
Table 1. The mean patient age was 19.8 years (range: 
2-51 years) and the mean duration of AD was 13.6 
years. Working criteria of AD severity referred to the 
grading of the clinical severity proposed by Miyakawa et 
al.10 By this criteria, 71.8% of patients had severe AD and 
the remaining 28.2% had moderate AD. Eruptions were 
of the flexural surface type in 87.5% of patients, of the 
head-face-neck-upper chest-upper back type in 96.8% 
of patients and of the erythroderma type in 34.1% of 
patients. Baseline laboratory data for these patients were
as follows: the mean (±SEM) total serum IgE was
6394±b88IU/mL, the mean (±SEM) CAP-RAST-levels to
Dermatophaqoides farinae (Df) and C. albicans were
158.9±30.5 and 18.7±2.3UA/mL, respectively, the
sum of CAP-RAST-class to five representative food 
allergens (including egg white, cows' milk, soy bean,
wheat and rice) was 2.8±0.3UA/mL. The mean lactate
dehydrogenase (LDH) value, which reflects the severity of
AD,11 was 575±20.3IU/L.
Oral ApB for recalcitrant AD
The prescription used forthe oral treatment of recalcitrant 
AD with ApB was ApB (Fungizone(R), Bristol-Myers Squibb 
K. K.) at 300-600mg/day, Clostridium butyricum 
MIYA-BM(R) fine granules (Miyarisan Pharmaceutical Co. 
Ltd) at 2.0-3.0g/day and a vitamin B complex at 2.0 
g/day. This prescription combined ApB with C. butyricum 
MIYAIRIC to inhibit the disturbance of normal flora in the 
gut and with a vitamin B complex to prevent vitamin 
deficiency; in addition, the intake of food allergens was 
restricted and foods, such as sweets, which facilitate 
Candida growth were avoided and a low yeast diet was 
maintained.
Overall assessment of treatment response
Overall assessment was made by evaluating the improve-
ment in subjective and objective symptoms, examining 
the doses of topical steroids used and noting the side 
effects of ApB. Patient responses to ApB treatment were 
classified as excellent, good, fair and useless or worse 
according to the following working criteria:
(1) Excellent: a marked improvement was noted and no 
topical steroids were needed on the face or on other 
lesions and no topical medicaments, skin care products 
or topical steroids of a milder class were used or were 
used on only a small area, depending on the subject. 
(2) Good: a definite improvement was noted, no topical 
steroids were used on the face or on other lesions and 
non-steroidal medicaments or topical steroids of a milder 
class were used in part. 
(3) Fair: a slight but insufficient improvement was noted, 
and patients became controllable with standard therapy, 
including topical steroids conventionally used. 
(4) Us less: symptoms were not improved by treatment or 
became worse and topical medicaments were not able to 
control refractory symptoms. 
 The total doses of topical steroids used were calculated 
according to each group (class II-IV), grading the topical 
st roid 12 during the period of assessment.
Comparative study for assessing the efficacy of 
oral ApB
As a control, the clinical improvement of 55 patients with 
AD who were treated by conventional therapy, without 
oral ApB, was monitored over a 3 and 6 month period. 
Controls included 12 patients who showed lower 
compliance (<25%) to therapy with oral ApB and other 
patients who did not receive ApB but who met the 
ind cations for oral ApB therapy.
Statistical analysis
The Kruskal-Wallis test, Mann-Whitney U-test, Wilcoxon
signed-ranktest, χ2 test and unpaired t-test were used to
test for significant differences.
RESULTS
CAP-RAST levels in subjects treated with oral 
ApB
Figure 1 shows the geometric means of CAP-RAST levels 
to C. albicans and Df and total serum IgE in three groups
of≦3,4-6 and≧7 according to the sum of CAP-RAST
class to five food allergens, including egg, milk, soy 
bean, rice and wheat. Using the unpaired t-test, there 
wer  significant differences found among the mean CAP-
RAST levels to C. albicans in the three groups. This 
suggests that in these subjects the sum of the CAP-RAST
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class to the five food allergens was associated with CAP-
RAST levels to C. albicans.
Efficacy of oral ApB on refractory symptoms
Table 2 shows the overall assessment of treatment 
response to oral ApB, evaluated according to the criteria 
described earlier. Symptoms that improved were dryness 
of the skin, erythema, severe itching, recurrent eczema 
and prurigo on the face and on other parts of the body. 
Times of assessment were expressed as mean days 
required for evaluating efficacy. The results of overall 
assessment were 'excellent' in 20% of subjects (25 of 125
patients) at 53.8±9.1 days, 'good' in 36.8% of subjects
(46 of 125 patients) at 92.9±10.2 days, 'fair' in 16% of
subjects (20 of 125 patients) at 94±22 days and
'useless' in 27.2% of subjects (34 patients, including 11
patients deemed 'worse') at 94.3±12.4 days.
Laboratory characteristics according efficacy
Statistical differences between clinical characteristics of 
subjects in whom treatment was assessed as excellent 
(group A), good (group B) and fair (group C) as well as 
those patients in whom treatment was assessed as useless 
(group D) were analyzed as shown in Table 3. There was 
no significant difference in the number of patients (%) with
serum IgE levels≧1000IU/mL, the geome ric mean of
CAP-RAST levels to C. albicans, the number of patients 
(%) who were positive for Candida spp. in the stools and 
the sum (mean) of CAP-RAST class to food allergens. The 
number of patients (%) adhering to the restricted diet was 
significantly higher in group B than in group D (P<
0.05), while the geometric mean of CAP-RAST levels to 
Df was significantly higher in group D than in group B 
(P<0.05).
Changes of laboratory data oral ApB
In patients in groups A, B and C (Table 3), it was 
determined that CAP-RAST levels of C. albicans were 
significantly lower after treatment with oral ApB com-
pared with levels prior to treatment (12.3±3.8 and
17.9±3.5UA/mL, respectively; P<0.01). The geo-
metric mean of IgE-radioimmunosorbent test (RIST) 
(P<0.01), CAP-BAST levels to egg white (P<0.01), soy 
bean (P<0.01), rice (P<0.05), wheat (P<0.01) and 
LDH (P<0.01)) were significantly lower after treatment 
with oral ApB than before treatment, as shown in Table 4.
Changes in doses of topical steroids used
The total doses of strong12 topical steroids (class II or III) 
decreased with improvements in AD due to treatment with 
oral ApB, as shown in Fig. 2. The average quantity of 
class IIItopical steroids prescribed in the ApB group after 
ApB therapy (total: n=61, 9.0g/2 weeks; A: n=12, 
2.8g/2 weeks) was significantly lower than that 
before treatment with ApB (total: n=48, 19g/2 weeks; 
A: n=9, 12.4g/2 weeks) and that in the control group 
(n=36, 13.3g/2 weeks; Fig. 2a). The number of 
patients with a decreased requirement for topical steroids 
was 91% of 21 patients using topical steroids in class II, 
80% of 48 patients in class III and 66% of 43 patients in 
class IV (Fig. 2b). The mean percentage decrease in the 
quantity of topical steroids prescribed during treatment
Fig. 1 Geometric means of CAP-RAST levels (UA/mL) to
Candida albicans (□) and Dermatophagoides farinae (Df; ■)
and total serum IgE (IU/mL; -◆-) in≦3,4-6 and ≧7 of three
groups according to the sum of CAP-RAST class to five 
representative food allergens, including egg white, cows' milk,
soy bean, wheat and rice.
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Table 2. Overall assessment of treatment response and days required for evaluating efficacy
Table 3. Characteristic background according to treatment response to oral amphotericin B
Table 4. Improvement of laboratory data in subjects who showed definite response to oral amphotericin B
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with ApB compared with that prescribed prior to
treatment was 57.4±13.9 in class II (n=21), 35.3±11
in class III (n=48) and 18.0±10.2 in class IV (n=43;
Fig. 2c).
Fig. 2 Changes in the quantity and quality of topical steroids 
prescribed during treatment with oral amphotericin B (ApB). 
The use of topical steroids was estimated by doses prescribed 
before treatment with ApB (Before) and during the final
assessment of overall improvement (After).
Comparative study in controls not treated with 
oral ApB
The pretreatment characteristics of the 125 patients 
receiving oral ApB were compared with pretreatment 
characteristics of 55 patients who did not receive ApB. 
There were no significant differences in age, gender, 
duration or severity of AD, type of eruptions, or 
adherence to dietary restrictions for food allergens 
between these two patient groups, as shown in Table 1. 
Laboratory evaluations of total serum IgE, CAP-RAST 
levels to C. albicans and the sum of positive CAP-RAST 
class to each food allergen also showed no significant 
differences between the patient groups (Table 1). With 
regard to the improvement of symptoms with oral ApB 
treatment, the percentage of patients treated with ApB 
who showed 'definite improvement' or 'remarkable 
improvement' was 16.8 and 53.6%, respectively, of 125 
cases over a 3 month period and 35.2 and 47.9%, 
respectively, of 71 cases over a 6 month period; this was 
significantly higher (P<0.01) than the 1.8 and 36.4%, 
respectively, of 55 controls over a 3 month period and 
8.3 and 36.1%, respectively, of 36 controls over a 6 
month period, as shown in Fig. 3.
Side effects of oral ApB for AD
Gastrointestinal symptoms, such as nausea (n=1), 
diarrhea (n=1) and abdominal pain (n=1), and 
aggravation of pruritus (n=2) were observed in a few 
patients (5/125; 4%). There were no laboratory 
abnormalities over a 6 month observation period.
DISCUSSION
The present study assessed anti-Candida therapy using 
oral ApB in treating recalcitrant AD that failed to respond 
to standard treatment. Efficacy was 'excellent' or 'good' 
in 56.8% of 125 patients, 'fair' in 16% of patients and 
'useless' in 27.2% of patients. This assessment was better 
than the overall efficacy of oral Ny, general efficacy which 
showed a rate of 49% in previous studies.7 Clinically 
recalcitrant lesions, including facial erythema and 
recurrent lesions refractory to topical steroids, were 
improved by ApB in subjects showing excellent or good 
efficacy. The mechanism by which oral ApB improved 
such refractory symptoms remains unknown. In a 
previous study13 we have shown that serum CAP-
RAST-IgE levels to C. albicans increase depending on the 
severity of AD. The Candida spp. are mainly resident flora
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Fig. 3 Improvement was assessed 3 
and 6 months (m) after oral 
amphotericin B (ApB) had started as
no change or worse (□), definite
improvement (□) or remarkable
improvement (■).
in vivo, although Candida spp. are also environmental 
fungi. Tanaka et al.14 demonstrated IgE-mediated 
hypersensitivity and contact sensitivity to a crude extract 
of C. albicans in patients with AD and also demonstrated 
a lower frequency of positivity on patch tests to C. 
albicans with simultaneously higher levels of RAST to C. 
albicans in the same group of patients. Those authors 
supposed that persistence of C. albicans in the digestive 
tract may induce a Th2-type T cell response. Savolainen 
et al.15 described that specific IgE to C. albicans 
increased and delayed hypersensitivity to C. albicans 
decreased in severe types of AD. It is suggested that 
unbalanced Th1/Th2 reactivity in AD patients is able to 
help saprophytic growth of those Candida spp. and to get 
patients with AD sensitized to antigens of these Candida 
spp. From this perspective, treatment of saprophytic 
Candida spp. in AD is needed to enable those patients to 
recover from refractory AD. Actually, in the present study, 
oral anti-Candida therapy helps symptoms to wane and 
reduces IgE specific to Candida. Oral anti-Candida 
therapy may reduce cross-reactive antibodies to 
Pityrosporum ovate/orbiculare, which are resident flora 
on the face, and this may also help to improve facial 
inflammation.17,18 According to the grade of efficacy,
there were no significant differences in CAP-RAST levels 
to C. albicans, the prevalence of Candida spp. in the 
stools or the sum of CAP-RAST class to food allergens in 
subjects in the present study. However, adherence to 
restrictions imposed for food allergy affected the efficacy 
of oral ApB, although the reason for this remains unclear. 
In our experience, orally administered ApB tablets show a 
reat r efficacy than does ApB syrup (data not shown). As 
the ApB tablet mainly targets fungi in the lower digestive 
tract in comparison with ApB syrup, we suppose that oral 
ApB targets Candida in the lower digestive tract. As the 
sum of the positive class of CAP-RAST to food allergens 
increased, CAP-RAST levels to Candida also increased. 
There were significant differences between pretreatment 
laboratory data, including mean CAP-RAST levels to food 
allergens, and data obtained 1 year or 6 months after 
treatment with ApB. Pretreatment CAP-RAST levels of C. 
albicans tended to be higher than those after treatment, 
but CAP-RAST levels to Df did not show any change after 
treatment. The laboratory diagnosis of overgrowth of 
Candida spp. and hypersensitivity to Candida in the 
digestive tract or yeast connection are not yet proven. 
However, based on the CAP-RAST data and on the 
clinical response to oral ApB tablets, intestinal Candida
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spp. or allergic reactions to Candida spp. in the intestine 
seem likely to increase the passage of food allergens 
through the intestinal wall. These data indicate that 
Candida in the digestive tract acts as an allergen carrier, 
helping food allergies to persist. Therefore, the oral 
administration of anti-Candida therapy along with the 
control of exposure to food allergens is necessary in 
recalcitrant AD accompanied by food allergy. 
  Furthermore, we recommended that patients receiving 
anti-Candida therapy follow a low yeast diet, as Candida 
are known to share some epitopes with Saccharomyces 
cerevisiae.16,18 However, it remains unknown whether S. 
cerevisiae, Aspergillus orysae, Saccharomyces rouxii and 
Lactobacillus casei, which are consumed with foods 
including bread, alcoholic beverages, soy sauce, miso 
and cheese, cause patients to become sensitized to 
Candida spp., thus aggravating or facilitating the 
persistence of AD in patients sensitized to Candida. 
 Efficacy of oral ApB was assessed after 3 and 6 
months. Better results were obtained earlier than were 
worse results. We assume that observations over periods 
longer than 3 months without signs of improvement are 
not useful in the evaluation of the efficacy of oral ApB on 
AD. 
 Other evidence of ApB efficacy included serum total
IgE, LDH11 and the fact that both doses and gradings of
the topical steroids used decreased in subjects showing 
significant improvement within 1 year or 6 months after 
oral ApB commenced. Although the frequency of 
recurrence of AD after discontinuing oral ApB was not 
examined in the present study, we did encounter some 
patients showing recurrent AD symptoms after 
discontinuing oral ApB. We would like to examine the 
prevalence of recurrence in subjects treated by oral ApB 
in the next study. The results obtained in patients using 
oral ApB demonstrated significant effectiveness of the 
treatment compared with results from controls. However, 
we must be cautious in interpreting the results of the 
present study, as 27.2% of patients receiving oral 
ApB did not respond to therapy. These patients had 
significantly higher IgE to Df. Therefore, environmental 
allergens would have to be more strictly 
controlled in these patients. As ApB is hardly absorbed 
through the gastrointestinal tract,19 when Candida 
infection becomes invasive, ApB does not affect the 
invasive lesions of intestinal candidiasis. Triazoles, such 
as fluconazole and itraconazole, may be suitable for 
such cases.4
 As indicated earlier, while aggravated or refractory AD 
appeared in patients who had high levels of specific IgE 
to C. albicans and food, the link with candidiasis in the 
dig stive tract is by association rather than by direct 
evidence. Mudde et al.20 showed that, in AD, epidermal 
Langerhans cells (LC) not bearing IgE present Candida 
allergens as do LC bearing IgE. Therefore, to examine 
levels of specific IgE to C. albicans is not enough to 
sug est an allergic reaction to Candida allergens in AD. 
Concerning the detection of the saprophytic growth of 
Candida spp., Buslau et al.21 have reported that yeasts 
were detected in stool samples from 70% of AD patients. 
The results of the present study did not show any 
difference in the prevalence of Candida spp. cultured 
from the feces of patients with AD compared with healthy 
subjects. In trials of serodiagnosis of Candida spp. 
overgrowth in the digestive system, D-arabinitol, an
enzyme secreted from Candida spp., or β-D-glucan, a
cell wall component of Candida spp., in sera are 
supposed to be available for some patients.22 However, 
as AD patients are not compromised hosts but have a
dis ased state, D-arabinitol or β-D-glucan are not
reliable indicators in all cases. Other methods of 
serodiagnosis for intestinal candidiasis are expected to 
be developed.
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